ICICI Securities Ltd | Retail Equity Research Revenues grew 3% YoY to | 3834 crore, above I-direct estimate of | 3574 crore. US sales declined 3% YoY to | 1607 crore (I-direct estimate: | 1434 crore) but grew 12% sequentially mainly due to gRenvela (nephrology) sales. India business grew 3% to | 613 crore (I-direct estimate: | 654 crore) EBITDA margins declined 254 bps YoY to 20.7% but came in above Idirect estimate of 18% mainly due to receiving milestone payment for an out licenced proprietary product of ~| 130 crore...